Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.03 mg (equivalent: estradiol, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red; propylene glycol - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 50 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; macrogol 3350; iron oxide yellow; iron oxide red; polyvinyl alcohol; sodium stearylfumarate; lactose monohydrate; purified talc; microcrystalline cellulose; silicon dioxide; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; purified talc; iron oxide yellow; silicon dioxide; polyvinyl alcohol; macrogol 3350; sodium stearylfumarate; titanium dioxide - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - abemaciclib, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; polyvinyl alcohol; microcrystalline cellulose; silicon dioxide; sodium stearylfumarate; titanium dioxide; macrogol 3350; purified talc - early breast cancer verzenio in combination with endocrine therapy is indicated for the adjuvant treatment of patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node-positive early breast cancer at high risk of recurrence.,in pre- or peri-menopausal women, endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.,advanced or metastatic breast cancer verzenio is indicated for the treatment of hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.,in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet); estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in grey tablet) 10 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in grey tablet) 1 mg; estradiol hemihydrate 1.03 mg eqv estradiol (micronised) (in white tablet) 1 mg

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - (blue tablet) estradiol hemihydrate 2.07mg equivalent to; (red tablet) estradiol hemihydrate 1.03mg equivalent to; (white tablet) estradiol as hemihydrate 2.07mg equivalent to; (white tablet) norethisterone acetate - tablet, film coated - 2 mg - (blue tablet) estradiol hemihydrate 2.07mg equivalent to 2 mg; (red tablet) estradiol hemihydrate 1.03mg equivalent to 1 mg; (white tablet) estradiol as hemihydrate 2.07mg equivalent to 2 mg; (white tablet) norethisterone acetate 1 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; titanium dioxide; lactose monohydrate; magnesium stearate; hydrogenated cottonseed oil; hypromellose; macrogol 6000; pregelatinised maize starch; povidone - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol hemihydrate, quantity: 2.06 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: maize starch; hypromellose; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised post menopausal women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use. in women with an intact uteri, use of opposed therapy must be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 1500; magnesium stearate; microcrystalline cellulose; glycol montanate; polacrilin potassium; titanium dioxide; hypromellose; hyprolose; macrogol 400 - 1. the prevention of pregnancy. 2. the treatment of moderate acne vulgaris not controlled with topical preparations in post-menarchal, pre-menopausal women who accept contraception.